
Phillip Oliver Coffin MD MIA, FACP, FIDSA (He/Him)
Addiction Medicine, Hospital Medicine/Hospitalist, Infectious Disease
Director of Substance Use Research
Join to View Full Profile
25 Van Ness AveSuite 500San Francisco, CA 94102
Dr. Coffin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of WashingtonFellowship, Infectious Disease, 2009 - 2012
- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
- University of California San Francisco School of MedicineClass of 2006
Certifications & Licensure
- CA State Medical License 2012 - 2027
- WA State Medical License 2009 - 2013
- NY State Medical License 2007 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
- American Board of Preventive Medicine Addiction Medicine
Clinical Trials
- Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals Start of enrollment: 2009 Mar 01
- Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors Start of enrollment: 2007 May 01
- Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM) Start of enrollment: 2007 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Mirtazapine reduces hypothetical methamphetamine demand in humans.Craig R Rush, Glenn-Milo Santos, Vanessa M McMahan, Annie Fraser, Jesse Clark
Drug and Alcohol Dependence. 2025-09-01 - Emergency medical system response, emergency department visits, and hospital admissions in response to non-fatal opioid overdoses reported by a cohort of overdose surv...Rachel J Smith, Vanessa M McMahan, Nicole C McCann, Sarah Kosakowski, Sarah Brennan
Drug and Alcohol Dependence Reports. 2025-09-01 - Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial.Manish K Jha, Udi E Ghitza, Steve Shoptaw, Abu Minhajuddin, Snoben Kuruvila
The Journal of Clinical Psychiatry. 2025-07-30
Authored Content
- Overdose Research PubMed UpdatesJanuary 2019
Press Mentions
- S.F. Is Giving ‘Chill Packs’ to Homeless Meth Users. Why It May Be a Promising InterventionAugust 26th, 2024
- Medication-Based Opioid Treatment on the Rise as San Francisco Grapples with OverdosesAugust 27th, 2022
- As Meth Wreaks Havoc on SF Emergency Rooms, Urgency Grows for New TreatmentsAugust 23rd, 2022
- Join now to see all
Grant Support
- Midcareer K24 Award for Mentoring and Patient-Oriented ResearchSAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH2023–2028
- Midcareer K24 Award for Mentoring and Patient-Oriented ResearchSAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH2023–2028
- PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025
- PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025
- PRIME: PrEP Intervention for people who Inject MEthamphetaminePUBLIC HEALTH FOUNDATION ENTERPRISES2020–2025
Professional Memberships
- Fellow
- Fellow
- College on Problems of Drug DependenceMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: